What is UPB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.26B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for UPB?

P/E (TTM) is n/a and 52-week range is $4.37 to $33.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s UPB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for UPB?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-15.61B, EPS (TTM) near $-2.89 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Upstream Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 54.4M shares outstanding, ISIN US91678A1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Upstream Bio Inc

$UPB

Health Care · Biotechnology

Run Scenarios

$4.70

+3.30%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Employees

Website

upstreambio.com/

IPO

2024-10-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)